Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Exclusion Criteria

• •Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
• •History of deep vein thrombosis or pulmonary embolus
• •Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while on study is acceptable.
• •History of a bleeding disorder or recent clinically significant bleeding
• •Seropositive for HIV
• •History of Hepatitis B, Hepatitis C, or chronic liver disease
• •Prior gene therapy or immunotherapy
• •Prior chemotherapy for prostate cancer
• •Radiation therapy within 4 weeks of the first treatment.
• •History of myocardial infarction within 6 months of the first treatment
• •History of cerebrovascular accident
• •History of previous malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
• •Evidence of active prostatitis
• •Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80